

# ACQUISITION OPPORTUNITY – CAROLINA, PUERTO RICO

## WORLD CLASS PARENTERAL FILL / FINISH MANUFACTURING OPERATION



Pfizer Inc has made the strategic decision to consolidate its manufacturing operations and is offering its Carolina, Puerto Rico, manufacturing site for sale. This site is focused on the manufacture of both  $\beta$ -lactam and non  $\beta$ -lactam lyophilized products and can easily be modified to produce powder fill vials. PharmaBioSource, Inc. is working with Pfizer to market the Puerto Rico-based sites that are being divested.

### **The Opportunity:**

The site, located in Carolina, Puerto Rico, approximately 14 miles (22 kilometers) from San Juan and 8 miles (13 kilometers) from the San Juan airport, is comprised of 545,000 square feet of space located on 20+ acres. The state-of-the-art manufacturing facility currently produces a range of products that service the US and international markets and represents a cost-effective alternative to new construction. Acquisition of the Carolina parenteral fill / finish manufacturing site provides:

- Access to two highly capable, fully separate aseptic manufacturing facilities; one for  $\beta$ -lactam products and one for non  $\beta$ -lactams.
- Access to a skilled Life Sciences work force.
- Excellent site infrastructure with opportunities for expansion or repurposing, such as biologics manufacturing.
- Facilities with an excellent regulatory approval record and ease of access to over 70 global markets including the US, Europe, Japan and Australia.
- The opportunity to take advantage of the favorable corporation tax regime in Puerto Rico to reduce taxes payable on global profits derived from pharmaceutical products manufactured on the Island.
- Up to 50% tax credit on qualified R&D expenses.



## Highlights of the facilities include:

- Isolated  $\beta$ -lactam aseptic manufacturing and packaging facilities for the manufacture of lyophilized products:
  - Three filling lines and thirteen lyophilizers provide flexibility for a wide range of vial sizes.
  - Facilities can accommodate powder fill vials with minimal equipment additions.
- Isolated non  $\beta$ -lactam aseptic manufacturing and packaging facilities for the manufacture of lyophilized and liquid fill products:
  - One filling line and two lyophilizers currently in operation.
  - Significant available space in aseptic core for additional filling lines / lyophilizers or other aseptic capabilities, i.e., biologics manufacturing.
- Laboratory and development facilities:
  - Modern, fully equipped QC laboratories as well as separate process development and technology transfer facilities including highly contained bench-scale test production facilities.
- Extensive utility infrastructure, warehouse facilities and administrative support facilities.



Interested parties should contact PharmaBioSource, Inc., the exclusive marketing firm for this opportunity, for more information regarding an acquisition of this World-Class Parenteral Fill / Finish manufacturing operation from Pfizer. Additional information is also available on its web site:

[www.pharmabiosource.com/pfizerdivestments](http://www.pharmabiosource.com/pfizerdivestments)

**FOR FURTHER INFORMATION, PLEASE CONTACT:**

**CHARLIE SHAFRAN**

Project Leader

Cell: 917.821.7693

[cshafran@pharmabiosource.com](mailto:cshafran@pharmabiosource.com)

**OLGA MORALES VENTURA**

Technical Information

Cell: 484.459.4943

[oventura@pharmabiosource.com](mailto:oventura@pharmabiosource.com)

**BILL WIEDERSEIM**

Technical Information

Cell: 610.888.9806

[wiederseim@pharmabiosource.com](mailto:wiederseim@pharmabiosource.com)

No representation or warranty, express or implied, is given by Pfizer, PharmaBioSource or their respective advisers or any of their respective directors, employees or contractors or any other person as to the accuracy or completeness of the contents of this summary information. The only representations and warranties that will be made are those that may eventually be included in a definitive agreement for the proposed transaction, if any. Neither this summary nor any of the information contained in it shall form the basis of an offer to purchase or acquire any shares, assets or interest in the facility.

